Corticoides pulmonares en pretérminos con dificultad respiratoria

1 Beck S, Wojdyla D, Say L, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010;88:31–8.

2 Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–72.

3 Organization WH. Preterm bith: fact sheet. 2016. http://www.who.int/mediacentre/ factsheets/fs363/en/

4 Askie LM, Henderson-Smart DJ, Jones RA. Management of infants with chronic lung disease of prematurity in Australasia. Early Hum Dev 2005;81:135–42.

5 Kotecha S. Management of infants with chronic lung disease of prematurity in various parts of the world. Elsevier 2005.

6 Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001;107:e1.

7 Li J, Wei K. Management of infants with chronic lung disease of prematurity in China. Early Hum Dev 2005;81:151–4.

8 Palomino MA, Morgues M, Martínez F. Management of infants with chronic lung disease of prematurity in Chile. Early Hum Dev 2005;81:143–9.

9 Shaw NJ, Kotecha S. Management of infants with chronic lung disease of prematurity in the United Kingdom. Early Hum Dev 2005;81:165–70.

10 Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev 2012;88:S27–S28.

11 Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357:1946–55.

12 Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev 2012;88 Suppl 2:S27–S28.

13 Doyle LW, Anderson P, Callanan C. Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991-1992. Pediatr Pulmonol 2006;41:570–6.

14 Vom Hove M, Prenzel F, Uhlig HH, et al. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 2014;164:e44:40–5.

15 Guardia CG, Moya FR, Sinha S, et al. A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa. J Pediatr Pharmacol Ther 2012;17:220–7.

16 Schwartz RM, Luby AM, Scanlon JW, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994;330:1476–80.

17 Maniscalco WM, Kendig JW, Shapiro DL. Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome. Pediatrics 1989;83:1–6.

18 Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009;36:177–88.

19 Gupta S, Prasanth K, Chen CM, et al. Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int J Pediatr 2012;2012:1–12.

20 Kugelman A, Durand M. A comprehensive approach to the prevention of bronchopulmonary dysplasia. Pediatr Pulmonol 2011;46:1153–65.

21 Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995;173:254–62.

22 Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2012:CD002058.

23 Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2012:CD002057.

24 Brownlee KG, Ng PC, Henderson MJ, et al. Catabolic effect of dexamethasone in the preterm baby. Arch Dis Child 1992;67:1–4.

25 Yeh TF, Lin YJ, Hsieh WS, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997;100:e3.

26 Nimmo AJ, Carstairs JR, Patole SK, et al. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol 2002;29:661–5.

27 Gupta S, Sinha SK, Donn SM. Myth: mechanical ventilation is a therapeutic relic. Seminars in Fetal and Neonatal Medicine 2011;16:275–8.

28 Chandler J, Churchill R, Higgins J, et al. Methodological standards for the conduct of new Cochrane Intervention Reviews. Sl: Cochrane Collaboration 2013.

29 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

30 Dastgiri S, Gilmour WH, Stone DH. Survival of children born with congenital anomalies. Arch Dis Child 2003;88:391–4.

31 Kao LS, Tyson JE, Blakely ML, et al. Clinical research methodology I: introduction to randomized trials. J Am Coll Surg 2008;206:361–9.

32 Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. J Clin Med 2017;6:4.

33 End note. A Smarter Way to Research. 2017. http://endnote.com

34 Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Vol 4: John Wiley & Sons 2011.

35 Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

36 community C. Reviwe Manager 5: Review Manager 5 (RevMan 5) is the software used for preparing and maintaining Cochrane Reviews. 2014. http://community.cochrane. org/tools/review-production-tools/revman-5

37 Yeh TF, Chen CM, Wu SY, et al. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2016;193:86–95.

38 Bassler D, Plavka R, Shinwell ES, et al. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med Overseas Ed 2015;373:1497–506.

39 Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med Overseas Ed 1999;340:1005–10.

40 Romagnoli C, Vento G, Zecca E, et al. A controlled trial of dexamethasone in preterm infants at risk of chronic lung disease. Rivista Italiana Di Pediatria-italian Journal Of Pediatrics 1998;24:283–8.